首页 > 最新文献

European annals of allergy and clinical immunology最新文献

英文 中文
A narrative review on allergy and exposure to domestic and non-domestic animals: favorable and unfavorable effects. 关于过敏与接触家畜和非家畜:有利和不利影响的叙述性综述。
IF 2.6 Q2 ALLERGY Pub Date : 2025-05-01 Epub Date: 2024-11-07 DOI: 10.23822/EurAnnACI.1764-1489.372
G Liccardi, M Martini, M B Bilò, L Cecchi, M Milanese, A Musarra, E Puxeddu, P Rogliani

Summary: The aim of this contribution was to highlight the "favorable" and "unfavorable" roles of domestic and non-domestic animals on airway sensitization processes and on the type/severity of the clinical symptoms induced by their exposure. We performed a literature research in MEDLINE for allergic manifestations and animals. Pets can be "allergy friends" through mechanisms related to hygiene hypothesis and translational aspects, the dual role of IgG4 antibodies for pets, and their promising role as healthcare service animals (dogs). On the contrary, animals can be "allergy enemies" when inducing allergic sensitization and  respiratory symptoms (sometimes leading to severe reactions), and also due to cross reactivity with other pets allergens, indirect exposure and ubiquity of their allergens, cross reactivity between Can f 5 and human prostate-specific antigen (PSA). Moreover, in some cases they can trigger anaphylaxis, induce occupational asthma, and act as pests. Finally, we must outline the modest efficacy of allergen immunotherapy (AIT) for their allergens. From a strictly allergological perspective, it is evident that the "negative" aspects resulting from exposure to domestic / non-domestic animals outweigh the "positive" aspects. As a consequence, it is up to humans to seek new ways to balance the pros and cons by exploring research areas that can allow the best possible coexistence with subjects at risk of allergy with domestic and non-domestic animals.

摘要:本文旨在强调家畜和非家畜对气道致敏过程的 "有利 "和 "不利 "作用,以及接触家畜所诱发的临床症状的类型/严重程度。我们在 MEDLINE 上对过敏表现和动物进行了文献研究。通过与卫生假说和转化相关的机制、宠物 IgG4 抗体的双重作用以及宠物作为医疗服务动物(狗)的前景,宠物可以成为 "过敏朋友"。相反,动物也可能成为过敏的 "敌人",因为它们会诱发过敏致敏和呼吸道症状(有时会导致严重反应),还会与其他宠物的过敏原发生交叉反应,间接接触过敏原,过敏原无处不在,Can f 5 与人类前列腺特异性抗原 (PSA) 发生交叉反应。此外,在某些情况下,它们还会引发过敏性休克、诱发职业性哮喘,并成为害虫。最后,我们必须概述一下过敏原免疫疗法(AIT)对其过敏原的适度疗效。从严格的过敏学角度来看,接触家养/非家养动物所产生的 "负面 "影响显然大于 "正面 "影响。因此,人类有责任寻找新的方法来平衡利弊,探索研究领域,让有过敏风险的受试者与家养动物和非家养动物以最佳方式共存。
{"title":"A narrative review on allergy and exposure to domestic and non-domestic animals: favorable and unfavorable effects.","authors":"G Liccardi, M Martini, M B Bilò, L Cecchi, M Milanese, A Musarra, E Puxeddu, P Rogliani","doi":"10.23822/EurAnnACI.1764-1489.372","DOIUrl":"10.23822/EurAnnACI.1764-1489.372","url":null,"abstract":"<p><strong>Summary: </strong>The aim of this contribution was to highlight the \"favorable\" and \"unfavorable\" roles of domestic and non-domestic animals on airway sensitization processes and on the type/severity of the clinical symptoms induced by their exposure. We performed a literature research in MEDLINE for allergic manifestations and animals. Pets can be \"allergy friends\" through mechanisms related to hygiene hypothesis and translational aspects, the dual role of IgG4 antibodies for pets, and their promising role as healthcare service animals (dogs). On the contrary, animals can be \"allergy enemies\" when inducing allergic sensitization and  respiratory symptoms (sometimes leading to severe reactions), and also due to cross reactivity with other pets allergens, indirect exposure and ubiquity of their allergens, cross reactivity between Can f 5 and human prostate-specific antigen (PSA). Moreover, in some cases they can trigger anaphylaxis, induce occupational asthma, and act as pests. Finally, we must outline the modest efficacy of allergen immunotherapy (AIT) for their allergens. From a strictly allergological perspective, it is evident that the \"negative\" aspects resulting from exposure to domestic / non-domestic animals outweigh the \"positive\" aspects. As a consequence, it is up to humans to seek new ways to balance the pros and cons by exploring research areas that can allow the best possible coexistence with subjects at risk of allergy with domestic and non-domestic animals.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"99-106"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anaphylaxis trend before and during pandemic: COVID-19 did not affect anaphylaxis frequency. 大流行前和期间的过敏反应趋势:COVID-19不影响过敏反应频率。
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-29 DOI: 10.23822/EurAnnACI.1764-1489.395
A Sangalli, A Fasiello, V Pravettoni, D Consonni, V Melli, A Jachetti, V Longo, N Montano, F Rivolta

Summary: Background. Data on epidemiology of anaphylaxis are difficult to record. During the lockdown in 2020-2021 due to Coronavirus disease 2019 (COVID-19), referrals to Emergency Department (E.D.) reduced. The aims of the study are to determine anaphylaxis frequency before and during COVID-19 pandemic and risk factors for severity. Methods. Clinical records from a general E.D. of Milan in Italy were retrospectively evaluated before (2018-2019) and during the COVID-19 pandemic (2020-2021) analyzing demographic data, comorbidities, chronic therapies, causes, severity and adrenaline use. Results. The frequency of anaphylaxis remained stable (120/104129 = 0.12% in 2018-2019; 72/66720 = 0.11% in 2020-2021). No differences in the occurrence of anaphylaxis were found in sex and mean age. The main causes of anaphylaxis were food (2018-2019: 53% vs 2020-2021: 51%) and drugs (2018-2019: 27% vs 2020-2021: 33%). Hymenoptera stings had a low occurrence and unidentified trigger was about 15% in each period. The severity of anaphylaxis had a similar distribution in the two periods. Gender and cardiovascular diseases did not influence the severity, instead a positive correlation was found in age over 50 yo (p<0.001). Angiotensin II receptors blockers, β-blockers, diuretics and proton pump inhibitors were associated with increasing severity (p<0.01). Adrenaline administration was similar in the two periods. Conclusions. Anaphylaxis frequency was not affected by the COVID-19 pandemic. Food anaphylaxis remained the most important cause in the urban area. The severity of anaphylaxis was affected by ageing and some chronic therapies, which indirectly point out the role of chronic diseases in the clinical presentation.

摘要:背景。关于过敏反应的流行病学数据很难记录。在2019冠状病毒病(COVID-19)导致的2020-2021年封锁期间,急诊科(ed)的转诊减少了。该研究的目的是确定COVID-19大流行之前和期间的过敏反应频率以及严重程度的危险因素。方法。回顾性评估了意大利米兰一家普通急诊室在2018-2019年和2020-2021年COVID-19大流行之前的临床记录,分析了人口统计数据、合并症、慢性治疗、原因、严重程度和肾上腺素使用情况。结果。2018-2019年,过敏反应发生频率保持稳定(120/104129 = 0.12%;72/66720 = 2020-2021年0.11%)。过敏反应的发生在性别和平均年龄上没有差异。过敏反应的主要原因是食物(2018-2019年:53%,2020-2021年:51%)和药物(2018-2019年:27%,2020-2021年:33%)。膜翅目昆虫蜇伤发生率较低,各时段不明原因蜇伤发生率约为15%。过敏反应的严重程度在两个时期有相似的分布。性别和心血管疾病不影响其严重程度,而在50岁以上的人群中存在正相关(p结论。过敏反应频率不受COVID-19大流行的影响。食物过敏反应仍然是城市地区最重要的原因。过敏反应的严重程度受年龄和一些慢性治疗的影响,这间接指出慢性疾病在临床表现中的作用。
{"title":"Anaphylaxis trend before and during pandemic: COVID-19 did not affect anaphylaxis frequency.","authors":"A Sangalli, A Fasiello, V Pravettoni, D Consonni, V Melli, A Jachetti, V Longo, N Montano, F Rivolta","doi":"10.23822/EurAnnACI.1764-1489.395","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.395","url":null,"abstract":"<p><strong>Summary: </strong><b>Background</b>. Data on epidemiology of anaphylaxis are difficult to record. During the lockdown in 2020-2021 due to Coronavirus disease 2019 (COVID-19), referrals to Emergency Department (E.D.) reduced. The aims of the study are to determine anaphylaxis frequency before and during COVID-19 pandemic and risk factors for severity. <b>Methods</b>. Clinical records from a general E.D. of Milan in Italy were retrospectively evaluated before (2018-2019) and during the COVID-19 pandemic (2020-2021) analyzing demographic data, comorbidities, chronic therapies, causes, severity and adrenaline use. <b>Results</b>. The frequency of anaphylaxis remained stable (120/104129 = 0.12% in 2018-2019; 72/66720 = 0.11% in 2020-2021). No differences in the occurrence of anaphylaxis were found in sex and mean age. The main causes of anaphylaxis were food (2018-2019: 53% vs 2020-2021: 51%) and drugs (2018-2019: 27% vs 2020-2021: 33%). Hymenoptera stings had a low occurrence and unidentified trigger was about 15% in each period. The severity of anaphylaxis had a similar distribution in the two periods. Gender and cardiovascular diseases did not influence the severity, instead a positive correlation was found in age over 50 yo (p<0.001). Angiotensin II receptors blockers, β-blockers, diuretics and proton pump inhibitors were associated with increasing severity (p<0.01). Adrenaline administration was similar in the two periods. <b>Conclusions</b>. Anaphylaxis frequency was not affected by the COVID-19 pandemic. Food anaphylaxis remained the most important cause in the urban area. The severity of anaphylaxis was affected by ageing and some chronic therapies, which indirectly point out the role of chronic diseases in the clinical presentation.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2-week time interval criterion may alter the spectrum of disease and patient characteristics in children diagnosed with hypereosinophilia. 2周时间间隔标准可能会改变诊断为嗜酸性粒细胞增多症的儿童的疾病谱和患者特征。
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-29 DOI: 10.23822/EurAnnACI.1764-1489.394
I C Maslak

Summary: Background. Diagnostic criteria for hypereosinophilia (HE) have been revised. Accordingly, the minimum interval between the two results with an absolute eosinophil count (AEC) ≥ 1500 cells/µL has been reduced from 4 to 2 weeks. The aims of this study were to identify patients with HE according to the new diagnostic criteria in children and demonstrate the effects of the revised time interval criterion on patient characteristics and disease spectrum. Methods. Individuals aged ≤ 18 years admitted to a tertiary university hospital were identified using an algorithm based on old and new diagnostic criteria for HE. While patients diagnosed with HE according to old diagnostic criteria were included in group 1, patients who were diagnosed with HE according to the new diagnostic criteria but did not meet the old criteria were included in group 2. Results. Patients in group 1 were significantly older than patients in group 2 at the time of diagnosis of HE (p = 0.004). While the number of patients diagnosed with HE aged 1-5 years was higher in group 1 (p = 0.01), the number of patients diagnosed with HE under the age of one year was higher in group 2 (p = 0.002). The most common cause of HE in group 1 was allergic disorders (10/40, 25%), while non-parasitic infections (17/36, 47%) were the most common diagnosis in group 2. Conclusions. The new diagnostic criteria may change the characteristics of pediatric patients with HE and the spectrum of associated diseases.

摘要:背景。嗜酸性粒细胞增多症(HE)的诊断标准已经修订。因此,绝对嗜酸性粒细胞计数(AEC)≥1500个细胞/µL的两个结果之间的最小间隔从4周减少到2周。本研究的目的是根据新的儿童诊断标准识别患有HE的患者,并证明修订后的时间间隔标准对患者特征和疾病谱系的影响。方法。使用基于新旧HE诊断标准的算法确定了在三级大学医院住院的年龄≤18岁的个体。根据旧诊断标准诊断为HE的患者被纳入1组,而根据新诊断标准诊断为HE但不符合旧诊断标准的患者被纳入2组。结果。组1患者在HE诊断时年龄明显大于组2患者(p = 0.004)。1 ~ 5岁HE患者在组1中较多(p = 0.01), 1岁以下HE患者在组2中较多(p = 0.002)。1组HE最常见的病因为过敏性疾病(10/40,25%),2组最常见的诊断为非寄生虫感染(17/36,47%)。结论。新的诊断标准可能会改变儿童HE患者的特征和相关疾病的谱。
{"title":"The 2-week time interval criterion may alter the spectrum of disease and patient characteristics in children diagnosed with hypereosinophilia.","authors":"I C Maslak","doi":"10.23822/EurAnnACI.1764-1489.394","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.394","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Diagnostic criteria for hypereosinophilia (HE) have been revised. Accordingly, the minimum interval between the two results with an absolute eosinophil count (AEC) ≥ 1500 cells/µL has been reduced from 4 to 2 weeks. The aims of this study were to identify patients with HE according to the new diagnostic criteria in children and demonstrate the effects of the revised time interval criterion on patient characteristics and disease spectrum. <b>Methods.</b> Individuals aged ≤ 18 years admitted to a tertiary university hospital were identified using an algorithm based on old and new diagnostic criteria for HE. While patients diagnosed with HE according to old diagnostic criteria were included in group 1, patients who were diagnosed with HE according to the new diagnostic criteria but did not meet the old criteria were included in group 2. <b>Results.</b> Patients in group 1 were significantly older than patients in group 2 at the time of diagnosis of HE (p = 0.004). While the number of patients diagnosed with HE aged 1-5 years was higher in group 1 (p = 0.01), the number of patients diagnosed with HE under the age of one year was higher in group 2 (p = 0.002). The most common cause of HE in group 1 was allergic disorders (10/40, 25%), while non-parasitic infections (17/36, 47%) were the most common diagnosis in group 2. <b>Conclusions.</b> The new diagnostic criteria may change the characteristics of pediatric patients with HE and the spectrum of associated diseases.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transitioning from nonspecific therapy to berotralstat in hereditary angioedema type I: real world data from three patients within the same family. 遗传性血管性水肿I型从非特异性治疗过渡到贝曲司他:来自同一家族三名患者的真实世界数据
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-29 DOI: 10.23822/EurAnnACI.1764-1489.391
D Vincent, A Ghanam
{"title":"Transitioning from nonspecific therapy to berotralstat in hereditary angioedema type I: real world data from three patients within the same family.","authors":"D Vincent, A Ghanam","doi":"10.23822/EurAnnACI.1764-1489.391","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.391","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-2 and the thymus/weight index are inversely correlated with gestational age: a sign of Th1/Th2 imbalance in preterm infants and a possible connection with atopic dermatitis. IL-2和胸腺/体重指数与胎龄呈负相关:这是早产儿Th1/Th2失衡的迹象,可能与特应性皮炎有关。
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-29 DOI: 10.23822/EurAnnACI.1764-1489.393
A Kowalik, Z Kwapińska, K Węglarczyk, M Stec, M Cisowska, M Siedlar, P Kwinta

Summary: Background. Understanding the reason for the decrease in atopic dermatitis risk in preterm patients may be crucial for the development of prophylaxis and therapeutic measures. The hypotheses include a change in T-helper1/T-helper2/T-helper17 balance, thymus development, and intestinal colonization. This study was designed to compare these parameters between preterm and term patients.  Methods. The investigated population comprised 28 preterm and 19 term-born patients. On the 7th day of life, T-helper1/T-helper2/T-helper17 cytokine concentrations were assessed, thymus ultrasonographic examination was performed, and the stool was examined for the presence of pathogenic bacteria. The last two procedures were repeated at 37 weeks of post-menstrual age in the preterm group. Results. There were no significant differences in the concentrations of interferon-γ, tumour necrosis factor-a (TNFa), interleukin (IL)-2, IL-6, or IL-10 after mitogen stimulation between the preterm and term groups. A negative correlation was found between IL-2 and the week of gestation at birth (rs= -0.466, p=0.038) and thymus/weight ratio and week of gestation at birth (rs= -0.592, p=0.006). IL-6 was negatively correlated with birth weight in preterm group (rs -0.694, p=0.008), whereas IL-10 positively with birth weight in term group (rs 0.775, p=0.041). Correlations of other investigated cytokines were statistically insignificant. The levels of IL-2 and interferon-γ after phytohemagglutinin stimulation were greater in the subgroup with pathogenic bacteria in the stool at birth (381.38 (148.7-727.4) vs. 13.23 (7.98-197.8) pg/ml; p=0.049; 17.49 (6.53-30.54) vs. 3.37 (1.03-9.82) pg/ml; p=0.037), whereas no significant differences were found between the levels of IL-6, IL-10 or TNFa. Conclusions. The observed associations may indicate an altered pattern of immunological development in preterm and term children.

摘要:背景。了解早产患者特应性皮炎风险降低的原因可能对预防和治疗措施的发展至关重要。这些假设包括T-helper1/T-helper2/T-helper17平衡、胸腺发育和肠道定植的改变。本研究旨在比较早产儿和足月患者的这些参数。方法。调查人群包括28名早产儿和19名足月患者。在出生第7天,检测T-helper1/T-helper2/T-helper17细胞因子浓度,胸腺超声检查,并检查粪便中是否存在致病菌。最后两个程序在早产组月经后37周重复。结果。在有丝分裂原刺激后,早产组和足月组之间的干扰素-γ、肿瘤坏死因子-a (TNFa)、白细胞介素(IL)-2、IL-6或IL-10的浓度无显著差异。IL-2与出生妊娠周(rs= -0.466, p=0.038)、胸腺/体重比与出生妊娠周(rs= -0.592, p=0.006)呈负相关。IL-6与早产儿出生体重呈负相关(rs -0.694, p=0.008), IL-10与足月组出生体重呈正相关(rs 0.775, p=0.041)。其他细胞因子的相关性无统计学意义。植物血凝素刺激后的IL-2和干扰素γ水平在出生时粪便中有致病菌的亚组中更高(381.38(148.7-727.4)比13.23 (7.98-197.8)pg/ml;p = 0.049;17.49 (6.53 ~ 30.54) vs. 3.37 (1.03 ~ 9.82) pg/ml;p=0.037),而IL-6、IL-10和TNFa水平之间无显著差异。结论。观察到的关联可能表明,在早产儿和足月儿童免疫发育模式的改变。
{"title":"IL-2 and the thymus/weight index are inversely correlated with gestational age: a sign of Th1/Th2 imbalance in preterm infants and a possible connection with atopic dermatitis.","authors":"A Kowalik, Z Kwapińska, K Węglarczyk, M Stec, M Cisowska, M Siedlar, P Kwinta","doi":"10.23822/EurAnnACI.1764-1489.393","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.393","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Understanding the reason for the decrease in atopic dermatitis risk in preterm patients may be crucial for the development of prophylaxis and therapeutic measures. The hypotheses include a change in T-helper1/T-helper2/T-helper17 balance, thymus development, and intestinal colonization. This study was designed to compare these parameters between preterm and term patients.  <b>Methods.</b> The investigated population comprised 28 preterm and 19 term-born patients. On the 7<sup>th</sup> day of life, T-helper1/T-helper2/T-helper17 cytokine concentrations were assessed, thymus ultrasonographic examination was performed, and the stool was examined for the presence of pathogenic bacteria. The last two procedures were repeated at 37 weeks of post-menstrual age in the preterm group. <b>Results.</b> There were no significant differences in the concentrations of interferon-γ, tumour necrosis factor-a (TNFa), interleukin (IL)-2, IL-6, or IL-10 after mitogen stimulation between the preterm and term groups. A negative correlation was found between IL-2 and the week of gestation at birth (r<sub>s</sub>= -0.466, p=0.038) and thymus/weight ratio and week of gestation at birth (r<sub>s</sub>= -0.592, p=0.006). IL-6 was negatively correlated with birth weight in preterm group (r<sub>s</sub> -0.694, p=0.008), whereas IL-10 positively with birth weight in term group (r<sub>s</sub> 0.775, p=0.041). Correlations of other investigated cytokines were statistically insignificant. The levels of IL-2 and interferon-γ after phytohemagglutinin stimulation were greater in the subgroup with pathogenic bacteria in the stool at birth (381.38 (148.7-727.4) vs. 13.23 (7.98-197.8) pg/ml; p=0.049; 17.49 (6.53-30.54) vs. 3.37 (1.03-9.82) pg/ml; p=0.037), whereas no significant differences were found between the levels of IL-6, IL-10 or TNFa. <b>Conclusions.</b> The observed associations may indicate an altered pattern of immunological development in preterm and term children.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergists versus pediatricians: primary choice of metered-dose inhaler with spacer or nebulizer. 过敏症专家与儿科医生:计量吸入器与间隔器或雾化器的主要选择。
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-29 DOI: 10.23822/EurAnnACI.1764-1489.392
S Melethil, E Yousef

Summary: Background. Many physicians believe delivering medications for asthma exacerbation via nebulizers is more efficacious than using a metered dose inhaler (MDI) with spacer. This study aimed to evaluate pediatricians and allergists' chosen method in children under 5 years: MDI with spacer or nebulizer. Methods. A brief survey was sent via electronic mail to a randomly selected group of pediatricians and allergists. There was a 15.8% (430/2718) total response rate. We divided respondents into 2 groups. Group A comprised 289 primary care pediatricians, and Group B included 141 practicing allergists. Results. In Group A, 68.5% (196/286) respondents indicated an MDI with spacer as their method of choice to deliver bronchodilator therapy during an asthma exacerbation; 64.7% (187/289) reported an MDI with spacer is an effective method; and 48% (135/281) believe delivering medication through a nebulizer will produce increased adverse effects than MDIs with spacers. In Group B, 55% (77/140) of respondents indicated MDI with spacer as their method of choice; 48.9% (69/141) reported a nebulizer is an effective method; and 65.7% (90/137) believe delivering medication through a nebulizer will produce increased adverse effects. Conclusions. Contrary to evidence-based recommendations, most allergists, compared to pediatricians, are not only prescribing nebulizers as their first choice for delivering bronchodilator therapy, but also half of these asthma specialists consider nebulizers to be an effective mode of delivery. As far as safety is concerned, ironically, almost two-thirds of allergists believe more side effects are associated with delivering bronchodilator therapy through a nebulizer.

摘要:背景。许多医生认为,通过雾化器给药比使用带间隔剂的计量吸入器(MDI)更有效。本研究旨在评估儿科医生和过敏症专科医生对5岁以下儿童MDI的选择方法:使用间隔器或雾化器。方法。一份简短的调查通过电子邮件发送给随机选择的一组儿科医生和过敏症专家。总有效率为15.8%(430/2718)。我们将受访者分为两组。A组包括289名初级保健儿科医生,B组包括141名执业过敏症专家。结果。在A组中,68.5%(196/286)的应答者表示,在哮喘发作期间,他们选择使用带间隔剂的MDI作为支气管扩张剂治疗的方法;64.7%(187/289)的患者认为MDI加隔离剂是有效的方法;48%(135/281)的受访者认为,通过雾化器给药会比使用间隔剂的吸入器产生更多的不良反应。在B组中,55%(77/140)的受访者表示MDI采用间隔器作为他们的选择方法;48.9%(69/141)的人认为雾化器是一种有效的方法;65.7%(90/137)的人认为通过雾化器给药会增加不良反应。结论。与循证建议相反,与儿科医生相比,大多数过敏症专家不仅将雾化器作为提供支气管扩张剂治疗的首选,而且这些哮喘专家中有一半认为雾化器是一种有效的递送方式。讽刺的是,就安全性而言,近三分之二的过敏症专家认为,通过雾化器进行支气管扩张剂治疗会产生更多的副作用。
{"title":"Allergists versus pediatricians: primary choice of metered-dose inhaler with spacer or nebulizer.","authors":"S Melethil, E Yousef","doi":"10.23822/EurAnnACI.1764-1489.392","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.392","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Many physicians believe delivering medications for asthma exacerbation via nebulizers is more efficacious than using a metered dose inhaler (MDI) with spacer. This study aimed to evaluate pediatricians and allergists' chosen method in children under 5 years: MDI with spacer or nebulizer. <b>Methods.</b> A brief survey was sent via electronic mail to a randomly selected group of pediatricians and allergists. There was a 15.8% (430/2718) total response rate. We divided respondents into 2 groups. Group A comprised 289 primary care pediatricians, and Group B included 141 practicing allergists. <b>Results.</b> In Group A, 68.5% (196/286) respondents indicated an MDI with spacer as their method of choice to deliver bronchodilator therapy during an asthma exacerbation; 64.7% (187/289) reported an MDI with spacer is an effective method; and 48% (135/281) believe delivering medication through a nebulizer will produce increased adverse effects than MDIs with spacers. In Group B, 55% (77/140) of respondents indicated MDI with spacer as their method of choice; 48.9% (69/141) reported a nebulizer is an effective method; and 65.7% (90/137) believe delivering medication through a nebulizer will produce increased adverse effects. <b>Conclusions.</b> Contrary to evidence-based recommendations, most allergists, compared to pediatricians, are not only prescribing nebulizers as their first choice for delivering bronchodilator therapy, but also half of these asthma specialists consider nebulizers to be an effective mode of delivery. As far as safety is concerned, ironically, almost two-thirds of allergists believe more side effects are associated with delivering bronchodilator therapy through a nebulizer.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining reference intervals for baseline serum tryptase: found the solution? 重新定义基准血清胰蛋白酶参考区间:找到解决方案了吗?
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-08 DOI: 10.23822/EurAnnACI.1764-1489.398
D Villalta, M Conte, D Visentini, M Furlani, F Ellero, R Metani, F Pesente, P Metus
{"title":"Redefining reference intervals for baseline serum tryptase: found the solution?","authors":"D Villalta, M Conte, D Visentini, M Furlani, F Ellero, R Metani, F Pesente, P Metus","doi":"10.23822/EurAnnACI.1764-1489.398","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.398","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delayed pressure urticaria affects chronic spontaneous urticaria treatment response: CURE insights. 迟发性压性荨麻疹影响慢性自发性荨麻疹治疗反应:CURE见解。
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-08 DOI: 10.23822/EurAnnACI.1764-1489.397
D Fomina, E Kovalkova, M Maurer
{"title":"Delayed pressure urticaria affects chronic spontaneous urticaria treatment response: CURE insights.","authors":"D Fomina, E Kovalkova, M Maurer","doi":"10.23822/EurAnnACI.1764-1489.397","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.397","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selective hypersensitivity to metamizole: role of specific IgE in the evaluation of immediate reactions. 选择性超敏:特异性IgE在评价即刻反应中的作用。
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-08 DOI: 10.23822/EurAnnACI.1764-1489.396
J Vieira, S Cosme Ferreira, D F Santos, M Paulino, S L Silva
{"title":"Selective hypersensitivity to metamizole: role of specific IgE in the evaluation of immediate reactions.","authors":"J Vieira, S Cosme Ferreira, D F Santos, M Paulino, S L Silva","doi":"10.23822/EurAnnACI.1764-1489.396","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.396","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Tezepelumab the treatment option of choice in severe allergic asthma? Tezepelumab是严重过敏性哮喘的治疗选择吗?
IF 2.6 Q2 ALLERGY Pub Date : 2025-04-08 DOI: 10.23822/EurAnnACI.1764-1489.399
A M Marra, B Biagioni, F Bini, L Cecchi
{"title":"Is Tezepelumab the treatment option of choice in severe allergic asthma?","authors":"A M Marra, B Biagioni, F Bini, L Cecchi","doi":"10.23822/EurAnnACI.1764-1489.399","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.399","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European annals of allergy and clinical immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1